Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription

Articles published in Semin Oncol

Retrieve available abstracts of 18 articles:
HTML format

Single Articles

    November 2019
  1. HOPKINS AM, Kichenadasse G, McKinnon RA, Rowland A, et al
    Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.
    Semin Oncol. 2019 Nov 6. pii: S0093-7754(19)30127.
    PubMed     Abstract available

    October 2019
  2. CHENG D, Ramos-Cejudo J, Tuck D, Elbers D, et al
    External validation of a prognostic model for mortality among patients with non-small-cell lung cancer using the Veterans Precision Oncology Data Commons.
    Semin Oncol. 2019 Oct 30. pii: S0093-7754(19)30055.
    PubMed     Abstract available

  3. KLEIN M, Scaria G, Ganti AK
    Utilization of the Veterans Affairs Central Cancer Registry to evaluate lung cancer outcomes.
    Semin Oncol. 2019 Oct 24. pii: S0093-7754(19)30063.
    PubMed     Abstract available

    September 2019
  4. MASOOD A, Kancha RK, Subramanian J
    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib.
    Semin Oncol. 2019 Sep 11. pii: S0093-7754(18)30191.
    PubMed     Abstract available

    April 2019
  5. TSAO A, Nakano T, Nowak AK, Popat S, et al
    Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
    Semin Oncol. 2019;46:145-154.
    PubMed     Abstract available

    October 2018
  6. MARUR S, Singh H, Mishra-Kalyani P, Larkins E, et al
    FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
    Semin Oncol. 2018 Oct 31. pii: S0093-7754(18)30157.
    PubMed     Abstract available

  7. KING-KALLIMANIS BL, Kanapuru B, Blumenthal GM, Theoret MR, et al
    Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1/PD-L1 therapy.
    Semin Oncol. 2018 Oct 25. pii: S0093-7754(18)30127.
    PubMed     Abstract available

  8. LAKING G, Evans J, Metcalfe S, Strother RM, et al
    Response to Cameron et al "Mind the graph" Semin Oncol. 2018.
    Semin Oncol. 2018;45.

  9. CAMERON L, Sullivan R, Luey B, Solomon B, et al
    Mind the Graph: Foregone Health Gains in Lung Cancer.
    Semin Oncol. 2018;45.

    July 2018
  10. SHINDE A, Li R, Kim J, Salgia R, et al
    Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly.
    Semin Oncol. 2018 Jul 1. pii: S0093-7754(18)30008.
    PubMed     Abstract available

    June 2018
  11. PILOTTO S, Carbognin L, Rossi A, Tortora G, et al
    Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?
    Semin Oncol. 2018;45:176-180.
    PubMed     Abstract available

    January 2018
  12. SANCHEZ L, Muchene L, Lorenzo-Luaces P, Viada C, et al
    Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer.
    Semin Oncol. 2018;45.
    PubMed     Abstract available

  13. SAAVEDRA D, Neninger E, Rodriguez C, Viada C, et al
    CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
    Semin Oncol. 2018;45.
    PubMed     Abstract available

    June 2017
  14. TABCHI S, Kassouf E, Rassy EE, Kourie HR, et al
    Management of stage III non-small cell lung cancer.
    Semin Oncol. 2017;44:163-177.
    PubMed     Abstract available

    April 2017
  15. PRASAD V, Kaestner V
    Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
    Semin Oncol. 2017;44:132-135.
    PubMed     Abstract available

    February 2017
    Commentary on "Screening for lung cancer" by Sateia et al.
    Semin Oncol. 2017;44:83-84.

  17. SATEIA HF, Choi Y, Stewart RW, Peairs KS, et al
    Screening for lung cancer.
    Semin Oncol. 2017;44:74-82.
    PubMed     Abstract available

  18. KAZANDJIAN D, Keegan P, Suzman DL, Pazdur R, et al
    Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials.
    Semin Oncol. 2017;44:3-7.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.